The Source

The Source Blog

Posts Tagged Under: Pharmaceutical

Litigation and Enforcement Highlights – June 2018

Pharmaceutical litigation and enforcement actions took the spotlight in the news last month. In this edition, we highlight two high profile enforcement cases and continue to follow the Allergan patent saga. In enforcement, we saw developments in the FTC’s antitrust enforcement against generic drug

Continue Reading

Download as PDF

The Source Roundup: June 2018 Edition

Happy June! In this edition of the Source Roundup, we cover five academic articles and reports from April and May. The topics this month include: (1) barriers for generics to lower specialty drug prices, (2) a call to reform pharmaceutical systems in the United States and Canada, (3) efforts by stat

Continue Reading

Download as PDF

Will Putting “American Patients First” Result in Lower Drug Prices?

On May 11, 2018, the Trump Administration released American Patients First, a blueprint to lower drug costs (the blueprint). The report details four challenges with the prescription drug market, including high list price

Continue Reading

Download as PDF

Litigation and Enforcement Highlights – May 2018

Several major court decisions were handed down last month that may leave lasting impacts in terms of price and competition in the healthcare industry. Specifically, the 4thCircuit Court of Appeals ruled Maryland’s Price Gouging Law unconstitutional, while the Supreme Court upheld inter

Continue Reading

Download as PDF

State Medicaid Programs are a Tool to Address Rising Drug Costs 

Rising prescription drug prices concern nearly all Americans, with 80% reporting that drug prices are “unreasonable”. The problem of rising drug expenditures is particularly acute for state Medicai

Continue Reading

Download as PDF

The Source Roundup: May 2018 Edition

Happy May! In this edition of the Source Roundup, we cover four academic articles and reports from March and April. The topics this month include: 1) the unfilled promise of price transparency to encourage price shopping, 2) FDA’s actions on prescription drug prices, 3) the phenomenon of overpayme

Continue Reading

Download as PDF